Call us at: 1.866.416.4636 | Europe: +800.0751.2020

Vevo MicroMarker Exploration Giveaway - Now Closed

Thanks to all those who participated in our Vevo MicroMarker Exploration Giveaway. The contest is now closed. Congratulations to all our winners!
 

About Vevo MicroMarker Contrast Agents

Microbubble contrast agents have been used in ultrasound imaging as a means of improving the visualization of blood flow with respect to the surrounding tissue. These micron-sized particles consist of a gas core surrounded by a lipid shell and are injected intravenously into the circulatory system. Understanding the patterns of blood flow is a powerful tool for evaluating the differences between normal and pathological tissues. 

These microbubbles can either be Non-targeted for visualization of blood flow and perfusion or conjugated to a molecular target (Target-Ready) to enable true in vivo molecular imaging.

Read below how Target-Ready Vevo®MicroMarkers are being used by researchers:


Vevo Blog:
Imaging with Bubbles…Next Generation Tool for Molecular Imaging?

The recent 2016 FDA approval of Bracco’s Lumason for its use in liver lesion detection for both adults and children, marks a milestone for microbubble imaging, paving the way for increased adoption and expanded clinical use of microbubbles in abdominal and pelvic imaging.

 

Terms and Conditions: Limited to one winner per laboratory group. NO PURCHASE OR PAYMENT OF ANY KIND IS NECESSARY TO ENTER OR  TO WIN. Limited quantities available. Subject to product availability. Submissions will be reviewed on an ongoing basis. Only winners will be notified within 4-6 weeks of proposal submission. Contest giveaway includes solely a 12 pack of target-ready of Vevo MicroMarker. contrast agents. No systems, accessories or other consumable materials are included. A Vevo imaging system must be used for data acquisition. Giveaway is only valid in the following regions: North America, South America, Europe, Australia, New Zealand, India. Contest closes January 31st, 2018 at 12 am EST.